Contraception A Comprehensive Review of Modern Methods, Clinical Efficacy, and Patient-Centered Care
1. Aidarbek kyzy Aidanek
2. Mohamed Yasir
Jothibasu Manoj
Mohamed Iliyas
(1. Lecturer, International Medical Faculty, Osh State University, Osh, Kyrgyz Republic.
2. Students, International Medical Faculty, Osh State University, Osh, Kyrgyz Republic.)
Abstract
Contraception represents one of the most significant public health achievements of the twentieth century, enabling individuals to exercise reproductive autonomy while reducing maternal and infant mortality worldwide. This comprehensive review examines the full spectrum of contemporary contraceptive methods, from long-acting reversible contraception to permanent sterilization, analyzing their mechanisms of action, efficacy profiles, and safety considerations. Drawing upon recent clinical guidelines and systematic evidence, we evaluate the comparative effectiveness of hormonal and non-hormonal approaches, with particular attention to the distinction between perfect-use and typical-use failure rates that fundamentally influences real-world outcomes. The analysis reveals that long-acting reversible contraceptives demonstrate superiority in effectiveness due to their independence from user adherence, while highlighting the nuanced risk-benefit profiles of hormonal methods regarding cardiovascular and oncological outcomes. Special populations including postpartum women, adolescents, and individuals with complex medical comorbidities require individualized approaches guided by evidence-based eligibility criteria. The integration of shared decision-making into contraceptive counseling emerges as essential for optimizing patient satisfaction and continuation rates. Future directions include the expansion of male contraceptive options and the development of novel delivery systems to further enhance accessibility and acceptability.
Introduction
The ability to control fertility through safe and effective contraception has transformed the landscape of reproductive health, enabling individuals to plan pregnancies according to their life circumstances, health status, and personal aspirations. Despite decades of progress, unintended pregnancy remains remarkably prevalent, with over forty percent of pregnancies worldwide classified as unintended, including forty-eight percent in North America and forty-three percent in Europe. These statistics underscore the persistent gap between contraceptive availability and optimal utilization, driven by barriers including cost, access limitations, misinformation, and method dissatisfaction. The consequences of unintended pregnancy extend beyond individual circumstances to encompass broader public health implications, including poorer maternal-infant birth outcomes, exacerbation of health inequities, increased poverty, and limitations on educational and economic advancement, particularly for women.
The contemporary contraceptive landscape offers unprecedented diversity in method choice, ranging from long-acting reversible contraceptives that provide years of protection with minimal user intervention to daily oral preparations and barrier methods requiring consistent use. This diversity, while empowering, also complicates clinical decision-making, as providers must navigate complex considerations including efficacy, safety, side effect profiles, reversibility, and alignment with patient preferences and life circumstances. The 2024 United States Selected Practice Recommendations for Contraceptive Use and the World Health Organization Medical Eligibility Criteria provide evidence-based frameworks for method selection across diverse populations, yet the translation of these guidelines into individualized patient care requires sophisticated clinical judgment and effective communication.
The concept of contraceptive efficacy itself demands careful examination, as the distinction between perfect-use and typical-use failure rates reveals the critical influence of human behavior on method performance. Long-acting reversible contraceptives, including intrauterine devices and subdermal implants, achieve failure rates below one percent annually through their independence from daily user action, while short-acting hormonal methods and barrier methods demonstrate substantially higher typical-use failure rates due to adherence challenges. This differential has profound implications for public health strategy and individual counseling, as the most effective method theoretically may not be the most effective method practically for a given individual if it conflicts with their preferences or capabilities.
This review aims to provide a comprehensive analysis of contemporary contraception, integrating pharmacological mechanisms with clinical evidence to guide informed method selection. We examine the major categories of contraceptive methods, their comparative effectiveness, safety profiles, and suitability for special populations, while emphasizing the importance of patient-centered counseling approaches. Through this synthesis, we seek to illuminate both current best practices and emerging developments in contraceptive care, supporting clinicians in optimizing reproductive health outcomes for diverse patient populations.
Methods of Contraception: Mechanisms and Clinical Profiles
Long-acting reversible contraception represents the most effective category of reversible contraceptive methods, comprising intrauterine devices and subdermal implants that provide sustained protection ranging from three to ten years. These methods achieve typical-use failure rates below one percent annually, approaching the efficacy of permanent sterilization while maintaining full reversibility upon removal. The 52 mg levonorgestrel-releasing intrauterine system, commercially available as Mirena, demonstrates sustained contraceptive efficacy for eight years based on recent data, having been extended from the original five-year approval in 2024 following evidence demonstrating comparable pregnancy prevention at eight years compared to five years of use. The 19.5 mg levonorgestrel intrauterine system maintains approved duration of five years, while the copper-containing intrauterine device provides ten years of highly effective contraception through spermicidal copper ion release.
The contraceptive implant, containing 68 mg etonogestrel, provides three years of protection through mechanisms including ovulation inhibition, cervical mucus thickening, and endometrial alterations. Recent multicountry studies have demonstrated extended efficacy beyond the approved three-year period, with serum etonogestrel levels remaining within contraceptive thresholds through four years of follow-up and no pregnancies reported among users extending use to four or five years. These findings suggest potential for extended use protocols, though current guidelines maintain the three-year replacement recommendation pending regulatory review.
The mechanism of action for hormonal intrauterine devices extends beyond local effects to include systemic progestin absorption, though at substantially lower levels than systemic hormonal methods. The levonorgestrel intrauterine system primarily achieves contraception through local endometrial effects including glandular atrophy and stromal decidualization, thickened cervical mucus impeding sperm penetration, and alterations in sperm and oocyte motility within the fallopian tubes. Ovulation inhibition occurs inconsistently, particularly with lower-dose devices, distinguishing these methods from systemic hormonal contraceptives that reliably suppress ovulation as their primary mechanism.
Copper intrauterine devices operate through fundamentally different mechanisms, releasing copper ions that create a spermicidal environment within the uterine cavity and fallopian tubes. The copper ion concentration achieves toxic effects on sperm, impairing motility and viability while simultaneously generating a sterile inflammatory response within the endometrium that is hostile to implantation. Unlike hormonal devices, copper intrauterine devices do not suppress ovulation or alter menstrual cycles hormonally, though they frequently produce changes in bleeding patterns including increased menstrual flow and intermenstrual spotting, particularly during initial months of use.
Short-acting hormonal contraceptives encompass combined hormonal methods containing estrogen and progestin, as well as progestin-only formulations, available through oral, transdermal, and vaginal delivery routes. Combined oral contraceptives, the most widely utilized hormonal method globally, achieve perfect-use failure rates of approximately 0.3 percent annually, though typical-use failure rates of 7 percent reflect the challenges of daily adherence. The contraceptive patch and vaginal ring offer alternative delivery routes with comparable efficacy, releasing ethinyl estradiol combined with progestin over weekly or three-week cycles respectively, though typical-use failure rates remain similar to oral preparations due to dependence on user adherence for replacement schedules.
Progestin-only methods include oral preparations, injectable formulations, and implantable devices, offering alternatives for individuals with contraindications to estrogen exposure. The progestin-only pill, historically limited to norethindrone formulations with relatively high failure rates due to short half-life and inconsistent ovulation inhibition, has been transformed by the introduction of drospirenone-containing preparations. Drospirenone progestin-only pills demonstrate ovulation inhibition exceeding 95 percent of cycles, comparable to combined oral contraceptives, with a 30-hour half-life permitting more flexible dosing than the three-hour window required for norethindrone preparations. This pharmacological advancement substantially reduces the contraceptive risk associated with missed pills, addressing a major limitation of traditional progestin-only oral contraception.
The contraceptive injection, primarily depot medroxyprogesterone acetate administered every three months, achieves high efficacy through reliable ovulation suppression and thick cervical mucus, with typical-use failure rates of 4 percent. However, the method's association with delayed return of fertility following discontinuation, often extending twelve months or longer, and concerns regarding bone mineral density effects with long-term use, have influenced its positioning in contemporary guidelines, particularly for adolescents and young adults where bone accrual remains ongoing.
Barrier methods, including male and female condoms, diaphragms, cervical caps, and spermicidal preparations, provide non-hormonal alternatives with the unique advantage of sexually transmitted infection protection for condom users. Male condoms demonstrate perfect-use failure rates of 2 percent, though typical-use failure rates of 13 percent reflect practical challenges including inconsistent use, breakage, and slippage. Female condoms offer alternative barrier protection with comparable efficacy, though lower acceptability and higher cost have limited widespread adoption. Diaphragms and cervical caps, requiring prescription fitting and consistent use with spermicidal agents, demonstrate typical-use failure rates of 12-17 percent, positioning them as less effective options suitable primarily for individuals with strong preferences for non-hormonal, user-controlled methods.
Emergency contraception provides post-coital pregnancy prevention through hormonal and copper intrauterine device options. Levonorgestrel emergency contraceptive pills, available without prescription in many jurisdictions, inhibit or delay ovulation when taken within 72 hours of unprotected intercourse, with efficacy declining over time and minimal effectiveness once luteinizing hormone surge has initiated ovulation. Ulipristal acetate, a selective progesterone receptor modulator, extends the effective window to 120 hours and demonstrates superior efficacy to levonorgestrel in some comparative studies, though access limitations including prescription requirements and higher cost influence utilization patterns. The copper intrauterine device provides the most effective emergency contraception, with failure rates below 0.1 percent when placed within five days of unprotected intercourse, while simultaneously providing ongoing contraceptive protection.
Permanent sterilization through tubal occlusion or vasectomy offers highly effective, irreversible contraception for individuals certain of their desire to avoid future fertility. Female sterilization demonstrates typical-use failure rates of 0.5 percent, while vasectomy achieves 0.15 percent failure rates with substantially lower procedural risk and cost. The increasing recognition of permanent sterilization regret, particularly among women sterilized at young ages or immediately postpartum, has prompted enhanced counseling requirements and consideration of long-acting reversible methods as alternatives even for individuals initially seeking permanent solutions.
Efficacy and the Role of User Adherence
The fundamental distinction between perfect-use and typical-use contraceptive efficacy reveals the critical importance of method characteristics that influence adherence. Long-acting reversible contraceptives achieve nearly identical perfect-use and typical-use failure rates because, once placed, they require no user action to maintain efficacy. This independence from daily behavior represents their primary advantage over short-acting methods, where the gap between theoretical and practical effectiveness can be substantial. Among participants in the Contraceptive CHOICE Project, a prospective cohort study providing comprehensive contraceptive counseling and no-cost access to all methods, pregnancy rates were 5 per 100 participant-years among pill, patch, and ring users compared to 0.3 per 100 participant-years among long-acting reversible contraceptive users. Notably, young age under 21 years doubled failure rates among short-acting method users but had no effect on long-acting reversible contraceptive failure rates, highlighting the particular value of these methods for adolescents and young adults who may struggle with consistent daily adherence.
The implications of these efficacy differentials extend beyond individual pregnancy prevention to population-level public health outcomes. When cost barriers are removed and comprehensive counseling provided, substantial shifts toward long-acting reversible contraceptive selection occur, with corresponding reductions in unintended pregnancy rates. The British Columbia universal no-cost contraception policy implemented in April 2023 demonstrated significant increases in long-acting reversible contraceptive dispensations across all age groups, with particularly pronounced effects among women aged 20-29 years, among whom dispensations increased to 1.70 times expected levels. These findings underscore the impact of financial and access barriers on method selection and the potential for policy interventions to improve contraceptive utilization patterns.
However, efficacy alone does not determine optimal method selection for individual patients. The contraceptive method that prevents pregnancy most effectively may not be the method that best meets an individual's needs, preferences, and circumstances if it conflicts with their desire for menstrual regularity, concerns about invasiveness, or preferences for non-hormonal approaches. The goal of contraceptive counseling is not to maximize efficacy for its own sake but to identify the method that a particular individual will use consistently and correctly, balancing efficacy against other valued attributes.
Safety Profiles and Risk Considerations
The safety of hormonal contraceptives has been extensively studied, with particular attention to cardiovascular and oncological outcomes that have shaped contemporary prescribing practices. Combined hormonal contraceptives increase risk of venous thromboembolism through estrogen-mediated effects on hepatic coagulation factor synthesis, generating a prothrombotic state. This risk varies substantially by estrogen dose and progestogen type, with modern low-dose preparations containing 20 micrograms ethinyl estradiol demonstrating lower thrombotic risk than higher-dose formulations. Progestogen selection further influences thrombotic risk, with levonorgestrel-containing combined oral contraceptives demonstrating relative risks of 3.6 compared to non-users, while desogestrel-containing preparations show relative risks of 5.6 and drospirenone-containing formulations relative risks of 7.3 in large case-control studies.
These relative risks, while statistically significant, must be interpreted in the context of absolute risk, as the baseline incidence of venous thromboembolism in young, healthy women is extremely low. The attributable risk associated with combined oral contraceptive use translates to approximately 3-9 additional venous thromboembolism events per 10,000 women per year, compared to 1-5 events per 10,000 among non-users. For most healthy young women, this small absolute risk is outweighed by the substantial benefits of effective contraception and non-contraceptive health advantages, though careful screening for additional risk factors including smoking, obesity, migraine with aura, and personal or family history of thrombotic events is essential.
Arterial cardiovascular events including myocardial infarction and ischemic stroke demonstrate similar associations with combined hormonal contraceptive use, though absolute risks remain extremely low in the absence of additional cardiovascular risk factors. Current or recent use of combined oral contraceptives is associated with approximately 1.5-2.0 times increased risk of arterial thrombosis, varying by estrogen dose and progestin type, with risk concentrated among women over 35 years and those with cardiovascular risk factors. Progestin-only contraceptives, including pills, implants, and injectables, demonstrate minimal if any increased cardiovascular risk, making them preferred options for women with contraindications to estrogen exposure.
Recent comprehensive cohort studies have clarified the relationship between hormonal contraceptives and breast cancer risk, demonstrating small but statistically significant increases associated with both combined and progestin-only formulations. Among 2.1 million Danish women followed for 21 million person-years, ever-use of any hormonal contraceptive was associated with a 24 percent increased breast cancer risk, corresponding to one additional case per 7,752 users annually. Both combined and progestin-only formulations demonstrated increased risk, with progestin-only methods showing slightly higher relative risks that may reflect longer duration of use in this population. Risk increased with duration of use, reaching 34 percent elevation for 5-10 years of use, but declined following discontinuation to baseline within 10-15 years.
Importantly, the absolute risk increase is small, particularly for young women where baseline breast cancer incidence is low. The 20 percent increased risk translates to approximately 8 additional cases per 100,000 users aged 16-20 years annually, compared to 265 additional cases per 100,000 users aged 35-39 years. These risks must be balanced against the substantial protective effects of hormonal contraceptives against ovarian and endometrial cancers, with meta-analyses demonstrating approximately 40-50 percent reduced risk of both malignancies that persists for decades following discontinuation. For every potential case of breast cancer attributed to hormonal contraceptive use, multiple cases of ovarian and endometrial cancer are prevented, generating net population benefit despite the small breast cancer elevation.
The copper intrauterine device demonstrates an excellent safety profile with minimal systemic effects, making it suitable for women with contraindications to hormonal methods. Primary adverse effects include increased menstrual bleeding and dysmenorrhea, particularly during initial months following insertion, which may improve over time but occasionally necessitate device removal. Concerns regarding pelvic inflammatory disease have been substantially mitigated by modern understanding that infection risk is primarily confined to the first three weeks following insertion, with no increased risk thereafter compared to non-users. Screening for sexually transmitted infections prior to insertion reduces this already low risk.
Special Populations and Clinical Considerations
Postpartum contraception requires careful timing considerations balancing pregnancy prevention needs against safety concerns. Combined hormonal contraceptives are contraindicated within 21 days postpartum due to elevated thromboembolism risk, and generally should be avoided until 42 days postpartum in breastfeeding women due to concerns about milk supply effects. Progestin-only methods, including implants and depot medroxyprogesterone acetate, may be initiated immediately postpartum, offering effective contraception without compromising breastfeeding establishment. Intrauterine devices may be placed immediately postpartum, though expulsion rates are higher than with interval placement, necessitating counseling about this risk and follow-up to confirm retention.
Adolescents represent a special population where long-acting reversible contraceptives demonstrate particular value due to high typical-use failure rates with short-acting methods in this age group. The American College of Obstetricians and Gynecologists recommends these methods as first-line options for adolescents, with counseling that addresses confidentiality, consent requirements, and the reversibility of these methods. Concerns about effects on future fertility are common among adolescents and parents, requiring clear explanation that these methods do not delay return to fertility following discontinuation beyond the normal range.
Women with medical comorbidities require individualized method selection guided by evidence-based eligibility criteria. The United States Medical Eligibility Criteria and World Health Organization Medical Eligibility Criteria categorize conditions according to whether they represent unacceptable health risks, advantages generally outweighing risks, or theoretical concerns without established risk. Conditions representing absolute contraindications to combined hormonal contraceptives include history of venous thromboembolism, ischemic cardiovascular disease, migraine with aura, active breast cancer, and severe cirrhosis, among others. Many of these conditions permit use of progestin-only or non-hormonal methods, emphasizing the importance of comprehensive counseling about alternatives.
Women with BRCA1 or BRCA2 mutations require particularly nuanced counseling regarding hormonal contraceptives. While oral contraceptives demonstrate substantial protective effects against ovarian cancer in this high-risk population, with hazard ratios of 0.55 for ever-use and 0.37 for use exceeding ten years, recent evidence suggests increased breast cancer risk among mutation carriers using oral contraceptives, with hazard ratios of 1.39 compared to non-users. This risk-benefit profile supports consideration of risk-reducing salpingectomy with ovarian conservation as an alternative strategy, or informed decision-making regarding hormonal contraception with careful surveillance.
Patient-Centered Counseling and Shared Decision-Making
The complexity of contraceptive method selection, involving trade-offs between efficacy, safety, side effects, and personal values, necessitates sophisticated counseling approaches that engage patients as active participants in decision-making. Shared decision-making, in which providers present evidence-based information about options while eliciting and respecting patient preferences, has emerged as the preferred model for contraceptive counseling. This approach contrasts with directive counseling that may prioritize provider preferences or method efficacy over individual patient values, potentially leading to method dissatisfaction and discontinuation.
Effective shared decision-making in contraception begins with eliciting patient reproductive goals, including desired timing of future pregnancy, and identifying any medical conditions that may influence method safety. Providers should then present information about available methods, including efficacy rates, side effect profiles, and non-contraceptive benefits, using visual aids and clear communication to support understanding. The Person-Centered Contraceptive Counseling measure provides a validated tool for assessing counseling quality, addressing whether patients feel listened to, respected, and supported in their decisions regardless of the method chosen.
Addressing misinformation represents a critical component of contemporary contraceptive counseling. Patients frequently encounter inaccurate information through social networks, media, and internet sources, generating concerns about method safety or efficacy that may influence decision-making. Providers must address these concerns respectfully, acknowledging the source of information while providing evidence-based correction, without dismissing patient concerns or creating defensiveness that may impair the therapeutic relationship.
The concept of contraceptive autonomy extends beyond method selection to include the right to discontinue use or switch methods without provider judgment or barriers. High discontinuation rates for many methods reflect both true medical intolerance and counseling failures that led to inappropriate initial selection. Supporting patients through method transitions, including managing side effects or addressing concerns that prompted discontinuation, represents an essential component of ongoing contraceptive care.
Future Directions
The landscape of contraception continues to evolve with development of novel methods and refinement of existing approaches. Male contraceptive development, long stalled despite substantial demand, has advanced with phase IIb trials of transdermal nestorone-testosterone gel demonstrating promising efficacy and acceptability. This hormonal approach suppresses spermatogenesis through progestin-mediated gonadotropin suppression with testosterone replacement to maintain androgen-dependent functions. If regulatory approval is achieved, this would represent the first novel male contraceptive method since the introduction of the condom and vasectomy, fundamentally expanding contraceptive responsibility sharing.
Novel delivery systems including biodegradable implants and extended-release formulations may further enhance the convenience and acceptability of long-acting methods. Research into non-hormonal contraceptive targets, including sperm-specific ion channels and proteins essential for fertilization, offers potential for methods that avoid the systemic effects of hormonal approaches while maintaining high efficacy.
The integration of digital health tools, including mobile applications for fertility awareness and medication reminders, may improve adherence to short-acting methods, though evidence regarding their effectiveness in reducing unintended pregnancy remains limited. Telemedicine approaches to contraceptive provision, expanded during the COVID-19 pandemic, offer potential to address access barriers, particularly for individuals in underserved areas, though ensuring appropriate screening for contraindications and follow-up care remains essential.
Conclusion
Contraception remains fundamental to reproductive health, enabling individuals to plan pregnancies according to their circumstances while providing substantial non-contraceptive health benefits. The contemporary method array offers unprecedented choice, from highly effective long-acting reversible contraceptives to diverse hormonal and non-hormonal alternatives suitable for varied preferences and medical circumstances. Optimal contraceptive care requires sophisticated clinical knowledge to navigate safety considerations, particularly regarding cardiovascular and oncological risks, combined with patient-centered counseling approaches that respect individual autonomy and preferences. As the field continues to evolve with development of male contraceptive options and novel delivery systems, the fundamental goal remains unchanged: ensuring that all individuals have access to safe, effective contraception that meets their needs and supports their reproductive goals.
References
1. Centers for Disease Control and Prevention. U.S. Selected Practice Recommendations for Contraceptive Use, 2024. MMWR Recomm Rep. 2024;73(RR-3):1-126.
2. Munro K, et al. Effect of universal no-cost coverage on use of long-acting reversible contraception and all prescription contraception: population based, controlled, interrupted time series analysis. BMJ. 2025;390:e083874.
3. Curtis KM, et al. U.S. Medical Eligibility Criteria for Contraceptive Use, 2016. MMWR Recomm Rep. 2016;65(3):1-103.
4. Faculty of Sexual and Reproductive Healthcare. UK Medical Eligibility Criteria for Contraceptive Use. 2016.
5. Peipert JF, et al. Preventing unintended pregnancies by providing no-cost contraception. Obstet Gynecol. 2012;120(6):1291-1297.
6. Winner B, et al. Effectiveness of long-acting reversible contraception. N Engl J Med. 2012;366(21):1998-2007.
7. Lidegaard Ø, et al. Thrombotic stroke and myocardial infarction with hormonal contraception. N Engl J Med. 2012;366(24):2257-2266.
8. Vinogradova Y, et al. Use of combined oral contraceptives and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases. BMJ. 2019;365:k2003.
9. Mørch LS, et al. Contemporary hormonal contraception and the risk of breast cancer. N Engl J Med. 2017;377(23):2228-2239.
10. Iversen L, et al. Lifetime cancer risk and combined oral contraceptives: the Royal College of General Practitioners' Oral Contraception Study. Am J Obstet Gynecol. 2017;216(6):580.e1-580.e9.
11. Jahanfar S, et al. Assessing the impact of contraceptive use on reproductive cancer risk among women of reproductive age—a systematic review. Front Glob Womens Health. 2024;5:1487820.
12. Asubiaro J. The Impact of Hormonal Contraceptives on the Incidence and Progression of Cardiovascular Diseases in Women: A Systematic Review. Cureus. 2024;16(8):e66428.
13. Nelson AL, et al. Contraceptive efficacy: essential concepts for counseling. Contraception. 2024;110(2):123-131.
14. Society of Family Planning. Clinical recommendations: contraception for adolescents. Contraception. 2020;102(6):363-371.
15. Blithe DL, et al. Contraceptive Development Program. NICHD Annual Report. 2024.
16. Bitzer J, et al. The new progestin-only pill with drospirenone 4mg: a comprehensive review of the evidence. Eur J Contracept Reprod Health Care. 2023;28(1):1-12.